Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma

J. F. Paone, T. P. Waalkes, R. Robinson Baker, J. H. Shaper

Research output: Contribution to journalArticle

Abstract

UDP-galactose:N-acetylglucosamine galactosyltransferase (GT) is a membrane-bound enzyme active in the biosynthesis of the carbohydrate moiety of glycoproteins and glycolipids. A soluble form of GT, present in human serum, has recently been found to be elevated in the presence of various neoplasms. In this study, GT levels were measured in randomized serum samples obtained from normal control (group I, n = 49), patients with benign breast disease (group II, n = 46), disease controls (group III, n = 50), patients with primary breast carcinoma (group IV, n = 53), and untreated metastatic breast cancer (group V, n = 23). Although substantial serum GT elevations were observed in individual control patients with active inflammatory or metabolic diseases, the mean GT levels were significantly higher in the groups with breast carcinoma (P <0.001, 0.001, 0.02; P <0.001, 0.001, 0.001 for groups IC and V vs groups I, II, and III, respectively). Furthermore, when serum GT levels were correlated with the preoperative clinical stage of breast cancer, significant elevations were found in 14.3% (3/21) of stage I, 66.7% (8/12) of stage II, 78.6% (11/14) of stage III, and 96.5% (28/29) of stage IV patients. These data indicate that serum GT levels are elevated in the presence of breast carcinoma and that the enzyme elevations correlate positively with the clinical stage of disease. Serum GT may be potentially useful in the detection of recurrent breast carcinoma and as a marker of tumor response to therapy for advanced disease.

Original languageEnglish (US)
Pages (from-to)59-66
Number of pages8
JournalJournal of Surgical Oncology
Volume15
Issue number1
StatePublished - 1980

Fingerprint

Galactosyltransferases
Uridine Diphosphate
Transferases
Biomarkers
Breast Neoplasms
Serum
N-Acetyllactosamine Synthase
Control Groups
Breast Diseases
Glycolipids
Metabolic Diseases
Enzymes
Tumor Biomarkers
Glycoproteins
Carbohydrates
Membranes

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma. / Paone, J. F.; Waalkes, T. P.; Baker, R. Robinson; Shaper, J. H.

In: Journal of Surgical Oncology, Vol. 15, No. 1, 1980, p. 59-66.

Research output: Contribution to journalArticle

Paone, J. F. ; Waalkes, T. P. ; Baker, R. Robinson ; Shaper, J. H. / Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma. In: Journal of Surgical Oncology. 1980 ; Vol. 15, No. 1. pp. 59-66.
@article{014cc37b320944819971b94af0114cea,
title = "Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma",
abstract = "UDP-galactose:N-acetylglucosamine galactosyltransferase (GT) is a membrane-bound enzyme active in the biosynthesis of the carbohydrate moiety of glycoproteins and glycolipids. A soluble form of GT, present in human serum, has recently been found to be elevated in the presence of various neoplasms. In this study, GT levels were measured in randomized serum samples obtained from normal control (group I, n = 49), patients with benign breast disease (group II, n = 46), disease controls (group III, n = 50), patients with primary breast carcinoma (group IV, n = 53), and untreated metastatic breast cancer (group V, n = 23). Although substantial serum GT elevations were observed in individual control patients with active inflammatory or metabolic diseases, the mean GT levels were significantly higher in the groups with breast carcinoma (P <0.001, 0.001, 0.02; P <0.001, 0.001, 0.001 for groups IC and V vs groups I, II, and III, respectively). Furthermore, when serum GT levels were correlated with the preoperative clinical stage of breast cancer, significant elevations were found in 14.3{\%} (3/21) of stage I, 66.7{\%} (8/12) of stage II, 78.6{\%} (11/14) of stage III, and 96.5{\%} (28/29) of stage IV patients. These data indicate that serum GT levels are elevated in the presence of breast carcinoma and that the enzyme elevations correlate positively with the clinical stage of disease. Serum GT may be potentially useful in the detection of recurrent breast carcinoma and as a marker of tumor response to therapy for advanced disease.",
author = "Paone, {J. F.} and Waalkes, {T. P.} and Baker, {R. Robinson} and Shaper, {J. H.}",
year = "1980",
language = "English (US)",
volume = "15",
pages = "59--66",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma

AU - Paone, J. F.

AU - Waalkes, T. P.

AU - Baker, R. Robinson

AU - Shaper, J. H.

PY - 1980

Y1 - 1980

N2 - UDP-galactose:N-acetylglucosamine galactosyltransferase (GT) is a membrane-bound enzyme active in the biosynthesis of the carbohydrate moiety of glycoproteins and glycolipids. A soluble form of GT, present in human serum, has recently been found to be elevated in the presence of various neoplasms. In this study, GT levels were measured in randomized serum samples obtained from normal control (group I, n = 49), patients with benign breast disease (group II, n = 46), disease controls (group III, n = 50), patients with primary breast carcinoma (group IV, n = 53), and untreated metastatic breast cancer (group V, n = 23). Although substantial serum GT elevations were observed in individual control patients with active inflammatory or metabolic diseases, the mean GT levels were significantly higher in the groups with breast carcinoma (P <0.001, 0.001, 0.02; P <0.001, 0.001, 0.001 for groups IC and V vs groups I, II, and III, respectively). Furthermore, when serum GT levels were correlated with the preoperative clinical stage of breast cancer, significant elevations were found in 14.3% (3/21) of stage I, 66.7% (8/12) of stage II, 78.6% (11/14) of stage III, and 96.5% (28/29) of stage IV patients. These data indicate that serum GT levels are elevated in the presence of breast carcinoma and that the enzyme elevations correlate positively with the clinical stage of disease. Serum GT may be potentially useful in the detection of recurrent breast carcinoma and as a marker of tumor response to therapy for advanced disease.

AB - UDP-galactose:N-acetylglucosamine galactosyltransferase (GT) is a membrane-bound enzyme active in the biosynthesis of the carbohydrate moiety of glycoproteins and glycolipids. A soluble form of GT, present in human serum, has recently been found to be elevated in the presence of various neoplasms. In this study, GT levels were measured in randomized serum samples obtained from normal control (group I, n = 49), patients with benign breast disease (group II, n = 46), disease controls (group III, n = 50), patients with primary breast carcinoma (group IV, n = 53), and untreated metastatic breast cancer (group V, n = 23). Although substantial serum GT elevations were observed in individual control patients with active inflammatory or metabolic diseases, the mean GT levels were significantly higher in the groups with breast carcinoma (P <0.001, 0.001, 0.02; P <0.001, 0.001, 0.001 for groups IC and V vs groups I, II, and III, respectively). Furthermore, when serum GT levels were correlated with the preoperative clinical stage of breast cancer, significant elevations were found in 14.3% (3/21) of stage I, 66.7% (8/12) of stage II, 78.6% (11/14) of stage III, and 96.5% (28/29) of stage IV patients. These data indicate that serum GT levels are elevated in the presence of breast carcinoma and that the enzyme elevations correlate positively with the clinical stage of disease. Serum GT may be potentially useful in the detection of recurrent breast carcinoma and as a marker of tumor response to therapy for advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=0018975882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018975882&partnerID=8YFLogxK

M3 - Article

C2 - 6775160

AN - SCOPUS:0018975882

VL - 15

SP - 59

EP - 66

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 1

ER -